In a recent issue of Asian Journal of Psychiatry, we presented a pragmatic hypothesis that the inclusion of guanidinoacetic acid (GAA) might offer an additional benefit in profiling inflammation-oxidative stress in schizophrenia. GAA concentrations in the brain, cerebrospinal fluid, serum, and urine are responsive to various brain conditions, including mental, behavioral and neurodevelopmental disorders. Specifically, GAA appears to be among the most sensible biomarkers of amino-acid metabolism in schizophrenia, with GAA has recently been cataloged in the group of potential metabolite signatures of the disease. Disturbances in GAA balance likely happen due to a GAA role in excess methylation, a well-recognized metabolic component of schizophrenia. Read more about this here.